MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.20
-0.04
-0.43%
After Hours: 9.20 0 0.00% 16:40 05/17 EDT
OPEN
9.39
PREV CLOSE
9.24
HIGH
9.50
LOW
8.80
VOLUME
1.84M
TURNOVER
0
52 WEEK HIGH
30.12
52 WEEK LOW
7.81
MARKET CAP
858.34M
P/E (TTM)
-3.0264
1D
5D
1M
3M
1Y
5Y
FibroGen stock jumps as strong roxadustat sales help drive Q1 earnings beat
Shares of FibroGen (NASDAQ:FGEN) have added 25.3% to $9.95 in Tuesday afternoon trading, after the biopharmaceutical company posted Q1 2022 earnings that beat estimates and raised its 2022 ending cash balance guidance.
Seekingalpha · 05/10 17:31
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:25
BRIEF-FibroGen Q1 Loss Per Share $0.68
reuters.com · 05/09 21:13
FibroGen Q1 EPS $(0.68) Beats $(0.83) Estimate, Sales $60.83M Up From $38.43M YoY
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.83) by 18.07 percent. This is a 12.82 percent increase over losses of $(0.78) per share from the same
Benzinga · 05/09 20:15
FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M
FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. Based on our latest forecast, we estimate a 2022 ending
Seekingalpha · 05/09 20:04
-- Earnings Flash (FGEN) FIBROGEN Reports Q1 Revenue $60.8M, vs. Street Est of $28.8M
MT Newswires · 05/09 16:29
FibroGen Q1 Loss Narrows, Revenue Rises
MT Newswires · 05/09 16:28
More
No Data
Learn about the latest financial forecast of FGEN. Analyze the recent business situations of Fibrogen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
85.71%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average FGEN stock price target is 13.40 with a high estimate of 25.00 and a low estimate of 9.00.
High25.00
Average13.40
Low9.00
Current 9.20
EPS
Actual
Estimate
-1.02-0.60-0.180.25
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 263
Institutional Holdings: 75.30M
% Owned: 80.71%
Shares Outstanding: 93.30M
TypeInstitutionsShares
Increased
48
7.33M
New
29
3.43M
Decreased
59
7.61M
Sold Out
28
1.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.35%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chairman/Director
James Schoeneck
Chief Executive Officer/Director
Enrique Conterno
Chief Financial Officer
Juan Graham
Senior Vice President
Christine Chung
Senior Vice President
Elias Kouchakji
Chief Scientific Officer
John Hunter
Other
Mark Eisner
Other
Thane Wettig
Lead Director/Independent Director
Thomas Kearns
Independent Director
Suzanne Blaug
Independent Director
Aoife Brennan
Independent Director
Benjamin Cravatt
Independent Director
Jeffrey Edwards
Independent Director
Jeffrey Henderson
Independent Director
Maykin Ho
Independent Director
Gerald Lema
Independent Director
Rory Riggs
No Data
No Data
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.